Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma
Status:
Not yet recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This is a single-arm and open-label study to explore XVRd (ATG-010, Bortezomib, Lenalidomide
and Dexamethasone) regimen in high-risk newly diagnosed multiple myeloma.The primary
objective of the dose escalation study is to determine the safety, tolerability, and
recommended phase II dose (RP2D) of selinexor; Then dose expansion at the RP2D level based on
dose escalation phase will be conducted to evaluate the efficacy, safety and tolerability.The
enrollment period for this study is expected to be approximately 12 months.
The study will end when all patients have completed 12 cycles treatment/follow-up since the
initiation of the study drug, or the last patient has expired, has been lost to follow-up, or
has withdrawn consent, whichever occurs first.